WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , Scientific Journal Impact Factor (SJIF) , IFSIJ Measure of Journal Quality , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , Research Publication Rating and Indexing , Doi-Digital Online Identifier , ISSN National Centre , Zenodo Indexing , International CODEN Service, USA , 

ISSN 2457-0400

Impact Factor  :  7.675

WJAHR Citation

  All Since 2020
 Citation  105  60
 h-index  4  4
 i10-index  3  2

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased from  5.464 to 7.675 for Year 2026.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR May 2026 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: MAY ISSUE PUBLISHED

    MAY 2026 Issue has been successfully launched on 1 MAY 2026.

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

  Indexing

  • Google Scholar
  • Index Copernicus
  • SOCOLAR, China
  • Research Bible, Fuchu, Tokyo. JAPAN
  • Cosmos Impact Factor
  • Scientific Indexing Services (SIS)
  • UDLedge Science Citation Index
  • International Impact Factor Services
  • International Society for Research Activity (ISRA) Journal Impact Factor (JIF)
  • Scientific Journal Impact Factor (SJIF)
  • IFSIJ Measure of Journal Quality
  • International Scientific Indexing, UAE (ISI) (Under Process)
  • International Impact Factor Services (IIFS)
  • Web of Science Group (Under Process)
  • Directory of Research Journals Indexing
  • Scholar Article Journal Index (SAJI)
  • International Scientific Indexing ( ISI )
  • Academia
  • Scope Database
  • Research Publication Rating and Indexing
  • Doi-Digital Online Identifier
  • ISSN National Centre
  • Zenodo Indexing
  • International CODEN Service, USA

Abstract

SAFETY AND EFFICACY OF FINERENONE IN PATIENTS WITH STAGE 2 & 3 CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES MELLITUS

Dr. Naveen Kumar Pothireddy*, Dontham Divya, Karumanchi Vyshnavi, Yendapalli Sonia, Uzma Qamar Ayesha, Dr. K. Jithender, Dr. M. Shiva Rama Krishna

ABSTRACT

Chronic kidney disease and Type-2 diabetes mellitus are two closely linked conditions. Diabetes is the leading cause of CKD, accounting for approximately 40% of all CKD cases. Finerenone is an oral agent, approved by the USFDA on July 9, 2021. The objective of the study to assess the safety and efficacy of Finerenone in patients with stage 2 & 3 chronic kidney disease with type 2 diabetes mellitus, while also monitoring specific biomarkers related to renal function. It was a prospective observational study conducted for a period of 6 months in a tertiary care hospital. The total subject volume are 50 patients with stage 2 & 3 chronic kidney disease with type 2 diabetes mellitus who under went treatment with Finerenone. The results of the study was most participants were early senior adult males, primarily aged over 60 (meanage- 65.5). Patients were prescribed with 10mg of Finerenone. Among 50 patients type 2DM and HTN are the most common combination of comorbidities making upto 20% of cases. whereas, no other 111 comorbidities (only diabetic nephropathy) accounting for the 66% of cases. Out of 50 patients the majority were in an early stage (2), while 26% each were categorized under stage 3a & 31b. In the duration of 90 days follow up the proteinuria, serum creatinine levels gradually decreased over time. Where as eGFR levels gradually increased over time. The serum potassium levels appear to have increased over the follow up period, a noticeable rise in potassium was observed only in 6 out of 50 patients. The drug proved to be effective in managing CKD progression with a favorable safety profile. The study concludes that Finerenone is effective in managing progression of CKD in stage 2 & 3 patients with type 2 diabetes mellitus, leading to a significant reduction in proteinuria, serum creatinine and significant improvement in eGFR levels. Although increase in serum potassium has seen in some of the patients as a side effect, overall adverse reactions were minimal. The drug offers substantial benefits for cardiovascular and renal protective with a generally favorable safety profile.

[Full Text Article] [Download Certificate]